SARS-CoV-2 immune response

SARS-CoV-2 immune response - SARS-CoV-2 Immune response

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON55057

Enrollment

800

Registered

2020-05-04

Start date

2021-10-05

Completion date

Unknown

Last updated

2024-04-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Before and after COVID-19 vaccination

Exclusion criteria

Exclusion criteria: < 18 years old

Design outcomes

Secondary

Measure	Time frame
• To determine the capability of the SARS-CoV-2 ELISpot to detect patients with a wide range of clinical manifestations with COVID-19 • To determine the dynamics in T-cell and B-cell response in time in COVID-19 patients • To determine differences in immune responses in severe, moderate and mild disease • To relate lineage strain diversity to disease and immune response • To determine biomarkers linked to development of severe, moderate or mild disease • To determine factors for (the development) of immunity to COVID-19	—

Measure

Time frame

• To determine the capability of the SARS-CoV-2 ELISpot to detect patients with a wide range of clinical manifestations with COVID-19 • To determine the dynamics in T-cell and B-cell response in time in COVID-19 patients • To determine differences in immune responses in severe, moderate and mild disease • To relate lineage strain diversity to disease and immune response • To determine biomarkers linked to development of severe, moderate or mild disease • To determine factors for (the development) of immunity to COVID-19

—

Primary

Measure	Time frame
To determine both T- and B-cell responses in COVID-19 patients.	—

Countries

Netherlands

Outcome results